Business, energy, technology, markets and global industry news from Business News Today

TECVAYLI

PharmaDeviceNews TECVAYLI
Representative image: CARVYKTI multiple myeloma treatment setting as Legend Biotech reports five-year progression-free survival after a single CAR T-cell infusion.
Pharma & Biotech

AbbVie submits FDA application for etentamig after Phase 3 CERVINO success in multiple myeloma

AbbVie seeks FDA approval for etentamig after Phase 3 myeloma results showed a 60% reduction in progression risk. Infection safety remains in focus.

Read More
Johnson & Johnson is moving Tecvayli toward much earlier European multiple myeloma treatment after Phase 3 data showed substantial progression-free and overall survival benefits. Representative image.
Pharma & Biotech

Johnson & Johnson’s Tecvayli cuts myeloma progression risk 71% as Europe considers much earlier use

European regulators have backed Tecvayli monotherapy after only one prior multiple myeloma treatment, potentially transforming Johnson & Johnson’s BCMA bispecific from a late-line therapy into a much larger second-line franchise.

Read More
European approval of teclistamab plus daratumumab follows MajesTEC-3 results showing an 83.4% reduction in the risk of progression or death and a significant overall-survival advantage versus established multiple myeloma regimens. Representative image.
Pharma & Biotech

Johnson & Johnson wins EU approval for TECVAYLI-DARZALEX as myeloma treatment moves earlier

Europe has approved teclistamab plus daratumumab after MajesTEC-3 showed an 83.4% reduction in progression or death and a significant overall-survival advantage versus established regimens.

Read More
A Phase 3 multiple myeloma research setting reflects Johnson & Johnson’s MonumenTAL-6 study, in which the Tecvayli-Talvey combination reportedly reduced the risk of disease progression or death by 89%. Representative image.
Pharma & Biotech

MonumenTAL-6 trial strengthens Johnson & Johnson’s dual-target multiple myeloma strategy

Johnson & Johnson’s Tecvayli-Talvey regimen cut progression risk by 89% in MonumenTAL-6. See what the topline data still must prove.

Read More
Pharma & Biotech

Johnson & Johnson strengthens its multiple myeloma franchise with TECVAYLI and DARZALEX FASPRO approval. What clinicians are watching next

FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.

Read More
Pharma & Biotech

J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results

FDA approves J&J's teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.

Read More
Pharma & Biotech

Johnson & Johnson’s TECVAYLI may redefine second-line myeloma care after MajesTEC-9

TECVAYLI outperformed standard regimens in relapsed/refractory myeloma. Find out what the Phase 3 MajesTEC-9 trial means for future treatment lines.

Read More
Pharma & Biotech

MajesTEC-3 results put Johnson & Johnson’s bispecific combo at center of myeloma care debate

TECVAYLI and DARZALEX FASPRO show major survival benefits in second-line multiple myeloma. Find out what the MajesTEC-3 trial means for clinical practice.

Read More